Intensity Therapeutics' Data on Lead Asset, INT230-6, Accept

/PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary,...

Related Keywords

Boston , Massachusetts , United States , Canada , Westport , Newfoundland , Vancouver , British Columbia , Ottawa , Ontario , Edna Kaplan , Merck Sharpe Dohme , Angel Arnaout , Jacob Stephen Thomas , Michael Miller , Bristol Myers Squibb , Matthew Ingham , Development Agreement , Ontario Institute Of Cancer Research , Ottawa Hospital Research Institute , National Cancer Institute , Society For Immunotherapy Of Cancer , Exhibition Center , Bristol Myers Squibb Company , Intensity Therapeutics Inc , Rx Communications Group , Vaccine Branch , Boston Convention , Connective Tissue Oncology Society , Vancouver Convention Center , York Presbyterian Hospital Columbia University Medical Center , Division Of Hematology , Two Poster Presentations Will Be Made , Metastatic Sarcomas Selected , Oral Podium Presentation , Intensity Therapeutics , Annual Meeting , Opportunity Trial Evaluating Cytotoxic , Early Stage Breast Cancer , Survival Results From , Intratumoral Agent , Induces Immunological Cancer Cell Death Alone , With Pembrolizumab , Assistant Professor , New York Presbyterian , Columbia University Medical , Ipilimumab Prolonged Survival , Favorable Safety , Refractory Sarcomas , Date Friday , Merck Sharpe , Ontario Institute , Cancer Research , Cooperative Research , Relations Contact , Nc ,